Arwen Stikvoort

About me
Publications
Grants
CV
Public outreach and news

About me

Arwen received her Master’s degree in Bio-medical sciences from Leiden university, the Netherlands in 2012. Her Ph.D in Medicine was obtained at Karolinska Institutet, Sweden in 2017. During her Ph.D Arwen’s research focused on the development and prediction of graft-versus-host disease and long-term hematopoietic mixed chimerism post hematopoietic stem cell transplantation. During a first Post doc position, she worked on the development of chimeric antigen receptor natural killer (CAR-NK) cells for the treatment of multiple myeloma at the Amsterdam UMC in the Netherlands.
Arwen then joined Professor Michael Uhlin’s lab in 2020 to work on the development of bispecific antibodies, especially NK cells and γδ T cells, to treat leukemia patients. Additionally, she will be working with tumor-infiltrating lymphocytes from human ovarian cancer patients with the aims to increase knowledge of the presence, phenotype and functionality of these T cells.

Articles

Article: ONCOIMMUNOLOGY. 2024;13(1):2379063
Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells
Al Agrafi F; Gaballa A; Hahn P; Arruda LCM; Jaramillo AC; Witsen M; Lehmann S; Onfelt B; Uhlin M; Stikvoort A
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023;149(8):4173-4184
Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines.
Al-Jamaei AAH; de Visscher JGAM; Forouzanfar T; Brakenhoff RH; Leemans CR; Stikvoort A; Zandieh-Doulabi B; Helder MN
Article: HAEMATOLOGICA. 2022;107(8):1786-1795
A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; de Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Article: HAEMATOLOGICA. 2022;107(2):437-445
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Article: HEMASPHERE. 2021;5(7):e596
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma
Stikvoort A; van der Schans J; Sarkar S; Poels R; Ruiter R; Naik J; Yuan H; de Bruijn JD; van de Donk NWCJ; Zweegman S; Themeli M; Groen R; O'Dwyer M; Mutis T
Article: HEMASPHERE. 2021;5(5):e561
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Holthof LC; Stikvoort A; van der Horst HJ; Gelderloos AT; Poels R; Li F; Groen RWJ; Zweegman S; van de Donk NWCJ; O'Dwyer M; Mutis T
Article: BONE MARROW TRANSPLANTATION. 2019;54(10):1562-1574
T-cell frequencies of CD8⁺ γδ and CD27⁺ γδ cells in the stem cell graft predict the outcome after allogeneic hematopoietic cell transplantation
Gaballa A; Stikvoort A; Onfelt B; Mattsson J; Sundin M; Watz E; Uhlin M
Article: ONCOIMMUNOLOGY. 2019;8(2):e1535730
Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
Radestad E; Klynning C; Stikvoort A; Mogensen O; Nava S; Magalhaes I; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2018;24(3):467-477
Risk Factors for Severe Acute Graft-versus-Host Disease in Donor Graft Composition
Stikvoort A; Gaballa A; Solders M; Nederlof I; Onfelt B; Sundberg B; Remberger M; Sundin M; Mattsson J; Uhlin M
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2017;101(3):623-632
Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells
Erkers T; Solders M; Verleng L; Bergstroem C; Stikvoort A; Rane L; Nava S; Ringden O; Kaipe H
Article: FRONTIERS IN IMMUNOLOGY. 2017;8:717
Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease
Stikvoort A; Chen Y; Radestad E; Torlen J; Lakshmikanth T; Bjorklund A; Mikes J; Achour A; Gertow J; Sundberg B; Remberger M; Sundin M; Mattsson J; Brodin P; Uhlin M
Article: PLOS ONE. 2016;11(5):e0154737
Long-Term Stable Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Patients with Non-Malignant Disease, Shall We Be Tolerant?
Stikvoort A; Sundin M; Uzunel M; Gertow J; Sundberg B; Schaffer M; Mattsson J; Uhlin M
Article: JOURNAL OF IMMUNOLOGY RESEARCH. 2016;2016:5601204-11
Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Sairafi D; Stikvoort A; Gertow J; Mattsson J; Uhlin M
Article: PROSTATE. 2014;74(14):1391-1399
Novel Method to Characterize Immune Cells From Human Prostate Tissue
Norstrom MM; Radestad E; Stikvoort A; Egevad L; Bergqvist M; Henningsohn L; Mattsson J; Levitsky V; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2013;19(5):838-844
Chimerism Patterns of Long-Term Stable Mixed Chimeras Posthematopoietic Stem Cell Transplantation in Patients with Nonmalignant Diseases: Follow-Up of Long-Term Stable Mixed Chimerism Patients
Stikvoort A; Gertow J; Sundin M; Remberger M; Mattsson J; Uhlin M
Journal article: JOURNAL OF BLOOD DISORDERS & TRANSFUSION. 2012;01(S1)
Mixed Chimerism after Allogeneic Stem Cell Transplantation – Focus on Double Cord Blood Transplantation
Jens G; Arwen S; Emma W; Jonas M

All other publications

Conference publication: BONE MARROW TRANSPLANTATION. 2023;58(SUPP1):355
GAMMA DELTA T CELLS RECONSTITUTION IN LONG-TERM SURVIVORS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Alagrafi F; Stikvoort A; Gaballa A; Arruda L; Poiret T; Uhlin M
Conference publication: BLOOD. 2022;140:8350
Comprehensive Exploration of NK Cell Education in ADCC Triggered By a Monoclonal Antibody or a Bispecific Killer Engager Molecule (BiKE)
Leijonhufvud C; Schlums H; Stikvoort A; Uhlin M; Bryceson YT; Carlsten M
Review: VIRUSES. 2021;13(6):1031
Revisiting the Role of γδ T Cells in Anti-CMV Immune Response after Transplantation
Gaballa A; Alagrafi F; Uhlin M; Stikvoort A
Meeting abstract: BLOOD. 2019;134:5536
Targeting CD38^high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells
Nolan E; Stikvoort A; Gurney M; Burduli N; Kirkham-McCarthy L; Daly J; Van de Donk NWCJ; Mutis T; Sarkar S; O'Dwyer ME
Meeting abstract: BLOOD. 2018;132:3199
CD38^low Natural Killer Cells Transiently Expressing CD16^F158V m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide
Sarkar S; Chauhan S; Stikvoort A; Natoni A; Daly J; Henderson R; Mutis T; O'Dwyer ME
Meeting abstract: BLOOD. 2018;132:3261
CD38 Specific Chimeric Antigen Receptor KHYG-1 Natural Killer Cells: A Potential "Off the Shelf" Therapy for Multiple Myeloma
Stikvoort A; Sarkar S; Poels R; van de Donk NWCJ; Zweegman S; O'Dwyer ME; Mutis T
Published conference paper: BONE MARROW TRANSPLANTATION. 2018;53(1):69-77
Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients
Gaballa A; Norberg A; Stikvoort A; Mattsson J; Sundberg B; Uzunel M; Remberger M; Uhlin M
Review: STEM CELLS INTERNATIONAL. 2017;2017:5738371-17
Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy
Erkers T; Stikvoort A; Uhlin M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):264
Identifying cellular subsets diagnostic for severity chronic GVHD
Stikvoort A; Chen Y; Radestad E; Karlsson-Torlen J; Tadepally L; Bjorklund A; Mikes J; Achour A; Gertow J; Sundberg B; Remberger M; Sundin M; Mattsson J; Brodin P; Uhlin M
Conference publication: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2017;86(4):265
Assessment of TREC, KREC and telomere length in long term survivors after allogeneic HSCT: the role of GVHD and graft source and evidence for telomere homeostasis in young recipients
Gaballa A; Norberg A; Stikvoort A; Mattsson J; Sundberg B; Uzunel M; Remberger M; Uhlin M
Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2016;17(10):1705
T Cell Receptor Excision Circle (TREC) Monitoring after Allogeneic Stem Cell Transplantation; a Predictive Marker for Complications and Clinical Outcome
Gaballa A; Sundin M; Stikvoort A; Abumaree M; Uzunel M; Sairafi D; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(3):S415
Identifying Cellular Subsets Diagnostic for Severity and Organ Specific Chronic GVHD
Stikvoort A; Rodestad E; Gertow J; Torlen J; Sundin M; Mattsson J; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(3):S179-S180
Prophylaxis for Herpes Simplex Virus Reactivation in Patients after Allogeneic Hematopoietic Stem Cell Transplantation; Effects and Clinical Outcome
Uhlin M; Stikvoort A; Sundin M; Mattsson J; Remberger M
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:845
Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells
Erkers T; Solders M; Verlang L; Bergstrom C; Stikvoort A; Rane L; Nava S; Ringden O; Kaipe H
Conference publication: EUROPEAN JOURNAL OF IMMUNOLOGY. 2016;46:844
Identifying cellular subsets diagnostic for severity and organ specificity chronic GVHD
Stikvoort A; Chen Y; Radestad E; Torlen J; Sundberg B; Sundin M; Mattsson J; Brodin P; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S351
An Increasing Severity of Chronic GvHD Is Associated to an Activated and Cytotoxic T Cell Mediated Immune-Phenotype
Stikvoort A; Radestad E; Torlen J; Mattsson J; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S182-S183
Long-Term Stable Mixed Chimerism in Patients Undergoing HSCT for Non-Malignant Disorders
Stikvoort A; Mattsson J; Sundin M; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(2):S170
Risk Factors and Clinical Outcome for Herpes Simplex Virus Reactivation in Patients after Allogeneic Hematopoietic Stem Cell Transplantation
Uhlin M; Stikvoort A; Sundin M; Mattsson J; Remberger M
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S407-S408
Risk factors and clinical outcome for Herpes Simplex Virus reactivation in patients after allogeneic hematopoietic stem cell transplantation
Uhlin M; Stikvoort A; Sundin M; Mattsson J; Remberger M
Conference publication: BONE MARROW TRANSPLANTATION. 2015;50:S236
Long-term stable mixed chimerism in patients undergoing HSCT for non-malignant disorders
Stikvoort A; Mattsson J; Sundin M; Uhlin M; Sundberg B; Uzunel M
Conference publication: HLA. 2014;84(1):32
AN INCREASING SEVERITY OF cGvHD IS ASSOCIATED TO A MORE ACTIVATED AND CYTOTOXIC T-CELL MEDIATED IMMUNE-PHENOTYPE
Stikvoort A; Radestad E; Gertow J; Sundin M; Mattsson J; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2014;49:S536-S537
AN INCREASING SEVERITY OF CGVHD IS ASSOCIATED TO A MORE ACTIVATED AND CYTOTOXIC T-CELL MEDIATED IMMUNE-PHENOTYPE
Stikvoort A; Radestad E; Gertow J; Sundin M; Mattsson J; Uhlin M
Conference publication: BONE MARROW TRANSPLANTATION. 2013;48:S248
Chimerism patterns of long-term stable mixed chimeras post-HSCT in patients with non-malignant diseases
Stikvoort A; Gertow J; Sundin M; Remberger M; Mattsson J; Uhlin M
Show more

Grants

Felix Mindus bidrag till leukemiforskningen
1 January 2024 - 31 December 2024
CIMED
1 January 2023 - 31 December 2025
Dr Åke Olssons stiftelse
1 January 2022 - 31 December 2022

Employments

Assistant Professor, Department of Medicine, Huddinge, Karolinska Institutet, 2024-2026
Assistant Professor, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2022-2024
Postdoctoral Researcher, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2020-2022
Postdoctoral researcher, Hematology, Amsterdam UMC, 2018-2020

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2017

About me

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI